Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 17/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 0.84 |
| ▸ | HTR2C | P28335 | 4/20 | 0.79 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972791 | 0.97 | HTR2B (0.95) | HTR2BHTR3AHTR2CPPARG | |
| SCHEMBL16972760 | 0.92 | HTR2B (1.00) | HTR2BHTR3AHTR2CPPARG | |
| SCHEMBL16972802 | 0.84 | HTR2B (0.76) | HTR2BHTR3AHTR2C | |
| SCHEMBL16972852 | 0.82 | HTR2B (1.00) | HTR2BHTR3AHTR2C | |
| SCHEMBL16972786 | 0.82 | HTR2B (0.79) | HTR2BHTR3AHTR2C | |
| SCHEMBL18417922 | 0.81 | HTR2B (1.00) | HTR2BHTR3AHTR2C | |
| SCHEMBL16972779 | 0.80 | HTR2B (0.74) | HTR2BHTR3AHTR2C | |
| SCHEMBL16972777 | 0.80 | HTR2B (1.00) | HTR2BHTR3AHTR2C | |
| SCHEMBL25262249 | 0.78 | HTR2B (0.78) | HTR2BHTR3AHTR2C | |
| SCHEMBL24227263 | 0.77 | PPARG (0.82) | HTR2BHTR3APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | US | claimed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | claimed |
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | claimed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | claimed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | claimed |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | disclosed |
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | HTR2B, HTR3B, HTR4 | HTR2B 1/4885HTR3A 11/4885HTR2C 5/4885 |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | ADORA2B, ADORA2A, ANXA3 | HTR2B 276/4885HTR3A 238/4885HTR2C 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.